UBS Group set a $250.00 target price on Allergan (NYSE:AGN) in a report published on Wednesday, www.tipranks.com reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also recently commented on AGN. Deutsche Bank restated a buy rating and set a $262.00 price objective on shares of Allergan in a research note on Tuesday, September 12th. Morgan Stanley cut Allergan from an overweight rating to an equal weight rating and reduced their price objective for the stock from $284.00 to $228.00 in a research note on Wednesday, September 20th. Citigroup restated a buy rating and set a $280.00 price objective on shares of Allergan in a research note on Wednesday, September 20th. Cantor Fitzgerald restated a hold rating and set a $231.00 price objective on shares of Allergan in a research note on Friday, September 22nd. Finally, Cowen restated an outperform rating and set a $400.00 price objective on shares of Allergan in a research note on Saturday, September 23rd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $226.95.

Allergan (NYSE:AGN) traded up $3.13 during mid-day trading on Wednesday, reaching $177.12. The company’s stock had a trading volume of 2,007,200 shares, compared to its average volume of 3,020,000. Allergan has a 1 year low of $160.07 and a 1 year high of $256.80. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The stock has a market capitalization of $57,870.00, a P/E ratio of -7.84, a PEG ratio of 1.18 and a beta of 1.11.

Allergan (NYSE:AGN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the business earned $3.32 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. equities analysts predict that Allergan will post 16.27 earnings per share for the current fiscal year.

Allergan declared that its board has approved a stock buyback program on Monday, September 25th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Friday, November 17th were paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.58%. The ex-dividend date of this dividend was Thursday, November 16th. Allergan’s dividend payout ratio (DPR) is -12.39%.

In related news, insider William Meury sold 11,807 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Chris W. Bodine purchased 3,030 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was acquired at an average price of $164.77 per share, for a total transaction of $499,253.10. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Howard Hughes Medical Institute acquired a new stake in Allergan during the second quarter valued at approximately $103,000. Cable Hill Partners LLC raised its stake in Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after buying an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. raised its stake in Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after buying an additional 400 shares in the last quarter. Massey Quick & Co. LLC raised its stake in Allergan by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after buying an additional 385 shares in the last quarter. Finally, Pacific Center for Financial Services raised its stake in Allergan by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after buying an additional 7 shares in the last quarter. Institutional investors and hedge funds own 81.14% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/01/11/allergan-agn-given-a-250-00-price-target-by-ubs-group-analysts.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Stock Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related stocks with our FREE daily email newsletter.